Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. George Walker, MD

Otolaryngology New Orleans, LA Male

NPI: 1326157496

Total Payments

$3,035

2023 Payments

$1,071

Companies

Transactions

Payment Breakdown by Category

Research$1,329 (43.8%)

Travel$1,125 (37.1%)

Food & Beverage$580.05 (19.1%)

Other$0.00 (0.0%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Unspecified	$1,329	9	43.8%
Travel and Lodging	$1,125	4	37.1%
Food and Beverage	$580.05	5	19.1%

Payments by Type

General

$1,705

9 transactions

Research

$1,329

9 transactions

Top Paying Companies

Company	Total	Records	Latest Year
Regeneron Pharmaceuticals, Inc.	$1,329	9	$0 (2018)
Genentech USA, Inc.	$1,071	3	$0 (2023)
Novartis Pharmaceuticals Corporation	$562.25	5	$0 (2019)
Scilex Pharmaceuticals Inc.	$72.59	1	$0 (2019)

Payment History by Year

Year	Amount	Transactions	Top Company
2023	$1,071	3	Genentech USA, Inc. ($1,071)
2019	$634.84	6	Novartis Pharmaceuticals Corporation ($562.25)
2018	$1,329	9	Regeneron Pharmaceuticals, Inc. ($1,329)

All Payment Transactions

18 individual payment records from CMS Open Payments

Date	Company	Product	Nature	Form	Amount	Type
03/30/2023	Genentech USA, Inc.	—	Food and Beverage	In-kind items and services	$197.46	General
03/29/2023	Genentech USA, Inc.	—	Travel and Lodging	Cash or cash equivalent	$444.79	General
03/29/2023	Genentech USA, Inc.	—	Travel and Lodging	Cash or cash equivalent	$428.27	General
09/13/2019	Novartis Pharmaceuticals Corporation	QBW251 (Drug)	Travel and Lodging	In-kind items and services	$220.08	General
09/13/2019	Novartis Pharmaceuticals Corporation	QBW251 (Drug)	Food and Beverage	In-kind items and services	$130.70	General
09/13/2019	Novartis Pharmaceuticals Corporation	QBW251 (Drug)	Travel and Lodging	Cash or cash equivalent	$32.17	General
09/12/2019	Novartis Pharmaceuticals Corporation	QBW251 (Drug)	Food and Beverage	In-kind items and services	$109.01	General
09/12/2019	Novartis Pharmaceuticals Corporation	QBW251 (Drug)	Food and Beverage	In-kind items and services	$70.29	General
06/08/2019	Scilex Pharmaceuticals Inc.	ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug)	Food and Beverage	In-kind items and services	$72.59	General
Category: Analgesic
07/20/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$98.06	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$380.90	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$87.97	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$84.99	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$50.04	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$38.38	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$20.00	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/27/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$20.00	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
04/07/2018	Regeneron Pharmaceuticals, Inc.	—	—	In-kind items and services	$548.95	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee	Regeneron Pharmaceuticals, Inc.	$1,329	9

About Dr. George Walker, MD

Dr. George Walker, MD is a Otolaryngology healthcare provider based in New Orleans, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326157496.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. George Walker, MD has received a total of $3,035 in payments from pharmaceutical and medical device companies, with $1,071 received in 2023. These payments were reported across 18 transactions from 4 companies. The most common payment nature is "" ($1,329).

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Otolaryngology
Location New Orleans, LA
Active Since 08/30/2006
Last Updated 07/08/2007
Taxonomy Code 207Y00000X
Entity Type Individual
NPI Number 1326157496

Products in Payments

QBW251 (Drug) $562.25
ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $72.59

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.